David C. U’Prichard, PhD, Venture Partner

Dr. U'Prichard has served as a Venture Partner at Red Abbey since January 2005 and a member of the firm’s Scientific Advisory Board since January 2004. He is currently the President of Druid Consulting LLC, a specialized pharmaceutical and biotechnology consulting firm which provides customized services to life sciences clients in the United States and Europe. From 2003 to 2006, Dr. U’Prichard was a Venture Partner at Apax Partners Ltd. (London, UK) and Care Capital, LLC (Princeton, NJ).

From 1999 to 2003, Dr. U’Prichard was the CEO of 3-Dimensional Pharmaceuticals, Inc. During his tenure at 3DP, Dr. U'Prichard was responsible for leading the private biotechnology company's successful initial public offering and completing major corporate alliances with Bristol-Myers Squibb Company and Johnson & Johnson Pharmaceutical Research and Development, LLC. In January 2003, he successfully negotiated the acquisition of 3DP by Johnson & Johnson Pharmaceutical Research and Development, LLC.

From 1997 to 1999, Dr. U'Prichard served as President of Research and Development at SmithKline Beecham. While at SmithKline Beecham, Dr. U'Prichard oversaw the entry of approximately ten compounds into global development, the international registration of a blockbuster diabetes drug and the entry of four compounds into Phase III trials and six compounds into early clinical trials. Additionally, he instituted several major restructuring efforts at the company. Prior to SmithKline Beecham, he worked for ICI/Zeneca from 1986 to 1997, serving as Executive Vice President and International Research Director from 1994 to 1997. While at Zeneca and SmithKline Beecham, Dr. U’Prichard oversaw the discovery and development of a number of successful drugs, including Seroquel®, Accolate®, Avandia® and Iressa®.

Previously, Dr. U'Prichard was instrumental in the launch of Nova Pharmaceuticals in 1983, following an academic career as a tenured Associate Professor of Pharmacology and Neurobiology at Northwestern University Medical School (1978-83), and his postdoctoral fellowship at Johns Hopkins University (1975-78). Dr. U'Prichard received his PhD in Pharmacology from the University of Kansas, and his BS in Pharmacology with first-class honors from the University of Glasgow, Scotland. He has held academic appointments at Northwestern University, Johns Hopkins University and the University of Pennsylvania, and is an Honorary Professor at the University of Glasgow. He is also an author of more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology, co-editor of Epinephrine in the Central Nervous System and has served as a member of various editorial boards. Dr. U'Prichard is Chairman of the Board of Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC, Berkeley Heights, NJ) and Oxagen Ltd (Oxford, UK) and serves on the Board of Directors of Invitrogen Corp (NASDAQ: IVGN, Carlsbad, CA), Alpharma Inc. (NYSE: ALO, Bridgewater, NJ) and Silence Therapeutics PLC (AIM:SLN, London, UK). Dr. U’Prichard was Chairman of the Pennsylvania Biotechnology Association in 2004-2005 and has served on the boards of BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, and Ben Franklin Technology Partners of Southeastern Pennsylvania. Dr. U’Prichard is a Trustee of the International House of Philadelphia and on the Board of the Bioethics Institute of the University of Pennsylvania.

*****
Contact David: duprichard@redabbey.com